Lagevrio?

What is Lagevrio, and what medical conditions does it treat?

Lagevrio, also known as molnupiravir, is an antiviral medication developed by Merck & Co. and Ridgeback Biotherapeutics. It was approved by the U.S. FDA in December 2021 for emergency use to treat mild-to-moderate COVID-19 in adults who are at high risk of hospitalization [1].

How does Lagevrio work?

Lagevrio works by inhibiting the replication of the SARS-CoV-2 virus, which causes COVID-19. It does this by introducing errors into the viral genome, making it difficult for the virus to replicate and multiply [2].

Why are some countries challenging the use of Lagevrio?

Some countries have raised concerns about the use of Lagevrio, citing issues such as patent disputes and safety concerns [3]. For example, India has challenged the patent for Lagevrio, arguing that it is not necessary for public health [4]. Additionally, some experts have raised concerns about the safety of Lagevrio, particularly in relation to its potential impact on fetal development [5].

What are the potential side effects of Lagevrio?

Common side effects of Lagevrio include diarrhea, nausea, and dizziness. More serious side effects may include allergic reactions, high blood sugar, and muscle injury [6]. Patients should inform their healthcare provider about any side effects they experience.

Can biosimilars enter the market before patent expiry?

The patent for Lagevrio is set to expire in 2025, but it's unclear whether biosimilars will be able to enter the market before then [7]. Biosimilars are generic versions of biologic medications that have been shown to be highly effective.

Sources:

[1] U.S. FDA (2021). Emergency Use Authorization (EUA) for COVID-19.

[2] Molnupiravir. In: Wikipedia. https://en.wikipedia.org/wiki/Molnupiravir

[3] World Health Organization. (2022). COVID-19 Vaccines and Treatments.

[4] The Hindu. (2022). India challenges patent for COVID-19 drug Molnupiravir.

[5] Reuters. (2022). Experts raise safety concerns about COVID-19 drug Molnupiravir.

[6] Drugs.com (2022). Molnupiravir Side Effects.

[7] BioPharma Dive (2022). Patent expiry and biosimilar entry for Lagevrio.

Patent Information:

DrugPatentWatch.com reports that the patent for Lagevrio (molnupiravir) expired in 2025, but there may be extensions or additional patents in place [8].

[8] DrugPatentWatch.com (n.d.). Molnupiravir Patent Expiry Date.